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ABSTRACT 
Background Studies exploring the relationship between prenatal vitamin D exposure and 
childhood asthma have yielded conflicting results. Higher vitamin D intake during pregnancy 
has been shown to lower the risk of childhood wheeze, yet a study of maternal late-pregnancy 
serum 25-hydroxyvitamin D suggested higher serum concentrations may be associated with 
increased childhood asthma.  
Objective  To assess the relationship between mothers’ serum 25-hydroxyvitamin D 
status and asthma and wheeze phenotypes in their children at age 6 years. Secondly, to 
explore the relationship between maternal 25-hydroxyvitamin D status and objective 
measures of childhood atopy and lung function. 
Methods Serum 25-hydroxyvitamin D was measured at 34 weeks’ gestation in the 
mothers of 860 children born at term. Wheeze was classified as either transient or 
persistent/late using questionnaire data collated from 6, 12, 24 and 36 months and 6 years. At 
6 years spirometry was performed and atopic status was determined by skin prick testing, 
exhaled nitric oxide was measured in 451 and bronchial hyperresponsiveness in 216 children.  
Results There were no significant associations between maternal late-pregnancy 25-
hydroxyvitamin D status and either asthma or wheeze at age 6 years. Maternal vitamin D 
status was not associated with transient or persistent/late wheeze; no significant association 
was found between persistent/late wheeze when subdivided according to atopic status. No 
associations were found with skin sensitisation or lung function.  
Conclusions This study provides no evidence that exposure to higher concentrations of 25-
hydroxyvitamin D in maternal serum during late pregnancy increases the risk of childhood 
asthma, wheeze or atopy.
INTRODUCTION 
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Vitamin D has multiple effects beyond those upon calcium metabolism and skeletal integrity. 
A role in asthma and atopic disease has been suggested as many immune cells possess 
vitamin D receptors[1] and genetic association has been demonstrated between variants in 
this receptor and asthma.[2] However, the relationship between vitamin D and asthma has 
proven controversial. Whilst Wjst and Dold proposed rising asthma prevalence to be a 
consequence of increased consumption of vitamin D-fortified foods,[3] Litonjua and Weiss 
argued, in contrast, that deficiency of vitamin D may be responsible.[4] Epidemiological 
support can be found for either viewpoint. A Southampton study found increased infantile 
eczema and childhood asthma in the children of mothers with higher late-pregnancy serum 
25-hydroxyvitamin D.[5] However, this small study was not specifically designed to look at 
atopic outcomes. Conversely, several cohort studies have found lower maternal vitamin D 
intake during pregnancy to be associated with increased childhood wheeze risk.[6-9]  
 
Serum 25-hydroxyvitamin D reflects total body vitamin D.[10] Most vitamin D is derived 
from photosynthesis in the skin.[10] Serum measures may more accurately characterise total 
exposure than estimated intake records which do not account for sun exposure. Maternal 25-
hydroxyvitamin D status was measured in the Dutch KOALA study but was not found to be 
associated with lung function at age 6 years; however, asthma prevalence, wheezing 
phenotypes and atopy were not assessed.[11] 
 
This is the first study to prospectively assess the relationship between maternal 25-
hydroxyvitamin D status during pregnancy and childhood asthma, wheeze and atopy and the 
first to consider wheeze separately in atopic and non-atopic children. This is important as 
persistent wheeze with atopy differs in clinical presentation from non-atopic persistent 
wheeze and is likely to be of separate aetiology.[12] Data from a large population-based 
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cohort were used to investigate whether higher maternal 25-hydroxyvitamin D status at 34 
weeks’ gestation is associated with increased childhood asthma or wheeze risk. Objective 
measures of lung function and skin sensitisation were used to test the secondary hypotheses 
that maternal 25-hydroxyvitamin D status is associated with evidence of altered immune or 
respiratory development.
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METHODS 
Participants 
Participants were mother-child pairs from the Southampton Women’s Survey.[13] Women 
aged 20-34 years were recruited during 1998-2002; those who became pregnant were 
followed through pregnancy and their children visited at 6, 12, 24 and 36 months and 6 years. 
To exclude effects of prematurity, whilst maximising power, infants born < 35 weeks’ 
gestation were excluded. Children aged six years during 2006-2010 were invited for follow-
up; 1485 mother-child pairs were eligible, maternal vitamin status and 6-year follow-up data 
were available for 860 pairs (Figure 1). Questionnaire data were collected during a home-visit, 
during this visit spirometry was also attempted. Due to resource limitations clinic-based 
bronchial provocation testing and exhaled nitric oxide measurements were limited to 
unselected subsets of participants. Parental consent was obtained and ethical approval was 
granted by the Southampton and South West Hampshire Local Research Ethics Committee 
(LREC Number 276/97, 307/97, 089/99 and 06/Q1702/104).  
 
Maternal serum 25-hydroxyvitamin D 
Maternal venous blood was sampled at 34 weeks’ gestation. To ensure stability samples were 
centrifuged, separated and stored at -80oC within 24 hours of sampling. 25-hydroxyvitamin D 
concentrations were measured by a Vitamin D External Quality Assessment Scheme 
compliant laboratory, with quality control samples in each batch. The radioimmunoassay 
used (DiaSorin, Minnesota, USA) had a coefficient of variability < 10%.  
 
Maternal vitamin D intake 
At 11 and 34 weeks’ gestation average frequencies of consumption over the preceding 3 
months were recorded using a 100-item food frequency questionnaire (FFQ). The FFQ has 
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been validated against 4-day food diaries and maternal micronutrient concentrations.[14] 
Nutrient intakes were calculated by multiplying frequency of consumption by nutrient 
content for each food or supplement. Early and late pregnancy intakes were averaged to 
provide an estimate of pregnancy intake. Energy adjustment can be used to correct for over or 
underestimation of intake in the FFQ, however, intake data were not automatically adjusted 
for total energy intake as supplementary intake vitamin D from supplements do not increase 
in line with energy intake. 
 
Atopy 
Skin prick testing was conducted at 1 and 3 years using cat, dog, house dust mite 
(Dermatophagoides pteronyssinus), grass pollens, egg and milk allergens (Hollister-Stier, 
Spokane, WA); at age 6, tree pollens (ALK Abelló Hørsholm, Denmark) were also tested. 
For validity a ≥ 3 mm positive and a 0 mm negative control response were required, atopy 
was defined as any allergen response ≥ 3 mm.  
 
Airway inflammation 
Exhaled nitric oxide (eNO) was measured online by trained research nurses according to 
ERS/ATS recommendations.[15] Measurements were recorded during controlled expiration 
at 50 ml/sec using a NIOX® chemiluminescence analyser (Aerocrine, Sweden). A mean value 
was calculated from three readings where possible. eNO data were normalised using an 
inverse square root transformation then standardised as a z-score. The sign of the values was 
reversed so that high untransformed eNO values gave rise to high standardised scores. 
 
Childhood asthma and wheeze  
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Respiratory assessment was conducted by research nurses using questions from the ISAAC 
core questionnaire wheezing module.[16] Specifically, mothers were asked at each visit 
whether their child had experienced ‘episodes of chestiness associated with wheezing or 
whistling in his/her chest since they were last seen’ and at 6 years whether their child had 
‘ever been diagnosed with asthma by a doctor’. The asthma outcome was refined to current 
asthma by including only 6-year-old children diagnosed with asthma who had experienced 
asthma symptoms or received asthma medication within the last year. The wheeze 
phenotypes were based upon those of the Tuscon Children’s Respiratory Study;[17] 
questionnaire data from 6, 12, 24 and 36 months and six years were combined to define: 
Transient wheeze: wheeze at ages 6, 12, 24 or 36 months but no wheeze and no asthma 
treatment at 6 years. 
Persistent wheeze: wheeze at ages 6, 12, 24 or 36 months and wheeze or asthma treatment at 
6 years. 
Late-onset wheeze: no wheeze at ages 6, 12, 24 or 36 months but wheeze or asthma treatment 
at 6 years. 
The persistent and late-onset groups were combined because the late-onset group contained 
few children (Figure1). The persistent/late wheeze group was sub-classified according to 
atopic status determined by skin prick testing.  
 
Lung function 
Spirometry was performed according to ATS/ERS guidelines,[18] although without noseclips 
to avoid discomfort. Flow-volume loops were measured for all children by experienced 
research nurses using a portable Koko spirometer with incentive software (KoKo version 4; 
PDS Instrumentation; Louisville, USA). Absolute values of FEV1 and FVC were recorded
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with and without standardisation for height to explore whether any effect of maternal 25-
hydroxyvitamin D status upon wheeze risk was mediated by an effect upon child’s height. 
 
Bronchial hyperresponsiveness (BHR) was measured by bronchial provocation challenge. 
Methacholine was administered using a dosimeter (Koko; PDS Instrumentation; Louisville, 
USA) and a compressed air-driven nebuliser (Sidestream®; Respironics, UK). Challenges 
were conducted according to ATS/ERS guidelines using incremental methacholine 
concentrations (0.06 mg/ml to 16 mg/ml).[19] Challenges were terminated following the 16 
mg/ml dose or a 20% fall in FEV1. BHR was expressed as the inverse of the slope of the 
regression line through FEV1 drop and logged methacholine concentration:  
Log.slope=100/[regression slope of FEV1 drop and log10(cumulative methacholine dose) + 10] 
The constant removes negative values and the inverse transformation produces a normally 
distributed variable.[20] Lower inverse log.slope values indicate increased BHR. 
 
Statistical methods 
Poisson regression with robust variance was used to model relative risk for binary outcomes. 
This is more appropriate than logistic regression for common outcomes where odds ratios 
cannot be interpreted as relative risks and so are hard to interpret.[21] Transient and 
persistent/late wheeze phenotypes were mutually exclusive; children suffering one of these 
types of wheeze were not at risk of the other so relative risks were calculated by comparing 
children with transient or persistent/late wheeze to those who had never wheezed. Relative 
risks for persistent/late wheeze with atopy and persistent/late wheeze without atopy were 
calculated using non-atopic children who had never wheezed as the comparator group. 
Relationships between maternal 25-hydroxyvitamin D status and continuous outcome 
variables were explored using linear regression.  
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Potential confounders were identified a priori and tested for association with each respiratory 
outcome. Models were developed comprising all the confounding variables listed in Table 1 
which were significantly associated with each outcome (p < 0.1). Birthweight and gestation 
were initially excluded from the multivariable models as they may lie on the causal pathway. 
Similarly, season and year of blood sampling were initially excluded from the multivariable 
models to preserve variation in the exposure variable which may drive an effect upon 
outcome. The analyses were repeated including these variables if they were significantly 
associated with the outcomes. 25-hydroxyvitamin D was analysed as a continuous variable to 
maximise power, however, the relationship between this exposure and each outcome was 
checked for linearity by fitting a quadratic term.  
 
As the analyses were designed a priori to test a limited number of hypotheses and not all the 
tests were independent, use of a Bonferroni correction was considered over-conservative.[22] 
As a compromise we focused on results with P-values ≤ 0.025 and considered consistency of 
the findings in our interpretation.
 Pike 11 
 
RESULTS 
Participants 
Participant mothers were broadly similar in terms of asthma, atopy and allergic disorders to 
those mothers for whom maternal 25-hydroxyvitamin D status or follow-up data were 
incomplete. Participant mothers were slightly older, taller, less likely to smoke in pregnancy, 
more likely to be primiparous and of higher educational attainment and social class than those 
with incomplete data. Participant children were less likely to be exposed to environmental 
tobacco smoke and more likely to have been breastfed than those with incomplete data (Table 
1). Similarly, those children contributing skin prick, spirometry, eNO or BHR data were 
broadly similar to those that did not. 
 
The median, (IQR) maternal 25-hydroxyvitamin D concentration was 59.0 nmol/l, (40.5-84.9 
nmol/l). The highest serum 25-hydroxyvitamin D value was 203 nmol/l, 29% of women had 
values greater than 80 nmol/l and 10% of women had serum levels greater than 110 nmol/l. 
Serum 25-hydroxyvitamin D concentrations were slightly lower in those women lost to 
follow-up (53.0, (38.5-79.2) nmol/l), probably reflecting socioeconomic and associated 
lifestyle factors. Eighty seven children (10.1%) had current doctor-diagnosed asthma, whilst 
504 (58.9%) had experienced wheeze at or before six years of age. A total of 137 (16.0 %) 
children were assigned to the persistent/late wheeze phenotype; of these 51.1 % were atopic 
and 48.9 % non-atopic (Table 2). Technically acceptable measures of FEV1, BHR and eNO 
were available from 739, 216 and 451 children respectively (Figure 1).
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Table 1 Comparison of SWS mother-child pairs with complete data with those lacking either 
maternal 25-hydroxyvitamin D or 6-year follow-up data but born in the same time period. 
 Mother-child pairs in 
analysis (n= 860) 
Mother-child pairs with 
missing data (n= 625) 
P-value 
Maternal characteristics    
Age at child’s birth (mean (SD)) 30.37 (3.81) 29.63 (3.76) <0.001 
Primiparous (n (%))     
No 462 (53.72) 369 (59.04) 0.042 
Yes 398 (46.28) 256 (40.96)  
Qualifications (n (%)) None  14 (1.63) 35 (5.61) 0.001 
GCSE D-G 84 (9.78) 67 (10.74)  
GCSE A*-C 248 (28.87) 179 (28.69)  
 A Level 249 (28.99) 186 (29.81)  
 HND 64 (7.45) 40 (6.41)  
 Degree 200 (23.28) 117 (18.75)  
Parents’ social class (n (%)) 1 88 (10.35) 57 (12.26) 0.031 
2 425 (50.00) 201 (43.23)  
 3N 234 (27.53) 123 (26.45)  
 3M 67 (7.88) 54 (11.61)  
 4 34 (4.00) 23 (4.95)  
 5 2 (0.24) 7 (1.51)  
Smoked in pregnancy (n (%))    
No 723 (85.46) 469 (78.17) <0.001 
Yes 123 (14.54) 131 (21.83)  
Maternal asthma (n (%))    
No 673 (78.9) 468 (75.97) 0.184 
Yes 180 (21.1) 148 (24.03)  
Maternal childhood eczema (n (%))    
No 703 (82.51) 501 (81.33) 0.561 
Yes 149 (17.49) 115 (18.67)  
Maternal rhinitis (n (%))    
No 494 (57.91) 372 (60.39) 0.341 
Yes 359 (42.09) 244 (39.61)  
Maternal atopy (n (%))    
No 406 (53.28) 255 (56.67) 0.253 
Yes 356 (46.72) 195 (43.33)  
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Pre-pregnancy BMI, kg/m2 (median (IQR))  24.32 (22.01-27.53) 24.05 (21.93-27.35) 0.996 
Height, cm (mean (SD)) 163.50 (6.65) 162.81 (6.01) 0.041 
Serum 25-hydroxyvitamin D, nmol/l (median (IQR)) 59.00 (40.52-84.89) 53.00 (38.47-79.19) 0.027 
Paternal characteristics    
Paternal asthma (n (%))    
No 697 (82.39) 486 (80.46) 0.351 
Yes 149 (17.61) 118 (19.54)  
Paternal childhood eczema (n (%))    
No 739 (88.29) 531 (88.06) 0.893 
Yes 98 (11.71) 72 (11.94)  
Paternal rhinitis (n (%))    
No 558 (66.59) 400 (66.12) 0.852 
Yes 280 (33.41) 205 (33.88)  
Child’s characteristics     
Gender (n (%))    
Male 445 (51.74) 333 (53.45) 0.516 
Female 415 (48.26) 290 (46.55)  
Birth weight, kg (mean (SD)) 3483.63 (494.52) 3467.09 (498.12) 0.529 
Gestational age, weeks (median (IQR)) 40 .14 (39.14-41.00) 40.14 (39.14-41.00) 0.914 
Months of breastfeeding  
(n (%)) 
None 132 (15.70) 131 (23.69) <0.001 
< 1 168 (19.98) 116 (20.98)  
1 - 3 157 (18.67) 122 (22.06)  
 4 – 6 156 (18.55) 72 (13.02)  
 7 – 11 139 (16.53) 81 (14.65)  
 12 or more 89 (10.58) 31 (5.61)  
Age of introduction solid food, weeks (median (IQR)) 17.38 (15.04-17.67) 17.38 (15.04-17.38) 0.282 
Mother smoked during child’s infancy (n (%))    
No 707 (82.88) 439 (76.88) 0.005 
Yes 146 (17.12) 132 (23.12)  
Cats/dogs in home during child’s infancy (n (%))    
No 432 (50.47) 295 (53.25) 0.307 
Yes 424 (49.53) 259 (46.75)  
Age at testing, years (median (IQR)) 6.46 (6.34-6.61) 6.44 (6.35-6.60) 0.797 
 
Binary outcomes were compared by χ2 test, categorical outcomes by a χ2 test for trend, and 
continuous variables using t-tests, after transformation where appropriate, or a ranksum test.
 Pike 14 
 
Table 2 Distribution of child participants between outcome groups. 
Wheeze outcome N (%) 
Current doctor-diagnosed asthma (aged 6 years) 87/860 (10.1) 
Current wheeze in the last 12 months (aged 6 years) 117/860 (13.6) 
Ever wheezed at or before 6 years 504/856 (58.9) 
Never wheezed 352/856 (41.8) 
Transient wheeze (before 3 years not after) 367/856 (42.0) 
Persistent/late wheeze (beyond or after 3 years) 137/856 (16.0) 
      Atopic persistent/late wheeze 46/632 (7.3) 
      Non-atopic persistent/late wheeze 48/632 (7.6) 
Atopic outcome  
Skin sensitisation 158/635 (24.9) 
Asthma and wheeze  
There was no significant association between maternal 25-hydroxyvitamin D status at 34 
weeks’ gestation and current asthma; neither was 25-hydroxyvitamin D status associated with 
wheeze at or before 6 years of age nor current wheeze in the 12 months preceding the 6-year 
assessment (Table 3). There were no significant associations with the transient or 
persistent/late wheeze phenotypes and subdividing the persistent/late phenotype by atopic 
status did not reveal any significant associations (Table 3). There was no evidence for a non-
linear relationship between maternal 25-hydroxyvitamin D and any wheeze phenotype (data 
not shown). 
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Table 3 Relationship between maternal late-pregnancy maternal 25-hydroxyvitamin D status and offspring asthma and wheeze at age 6 years 
  
Univariable Model 
 
 
 
Final model 
  
 
RR (95% CI) P-value n  RR (95% CI) P-value n 
Current doctor-diagnosed asthma at 6 years 0.97 (0.91, 1.04) 0.36 860  0.98 (0.92, 1.04) 0.56 836 
Current wheeze at 6 years 0.98 (0.92, 1.03) 0.40 860  0.99 (0.94, 1.05) 0.76 833 
Any wheeze at or before 6 years 1.00 (0.98, 1.01) 0.61 856  1.00 (0.98, 1.02) 0.95  823 
Transient wheeze 1.00 (0.98, 1.02) 0.85 719  1.00 (0.98, 1.02) 0.89 707 
Persistent/late wheeze 0.98 (0.93, 1.03) 0.37 489  0.98 (0.94, 1.03) 0.49 475 
     Persistent/late wheeze with atopy 0.90 (0.81, 0.99) 0.03 257  0.91 (0.84, 0.99) 0.04 251 
     Persistent/late wheeze without atopy 0.99 (0.91, 1.06) 0.73 259  1.01 (0.94, 1.09) 0.73 253 
 
Data presented as change in relative risk per 10 nmol/l change in maternal serum 25-hydroxyvitamin D status at 34 weeks’ pregnancy. 
Adjusted models: asthma - maternal education, maternal asthma, paternal asthma and paternal rhinitis; wheeze at age 6 - maternal education, 
maternal asthma, paternal rhinitis, pets in the home during the child’s infancy; wheeze at or before 6 years - maternal BMI, child’s gender, 
maternal education, maternal asthma, paternal asthma, maternal rhinitis; transient wheeze - maternal BMI, child’s gender, mother’s parity, 
maternal asthma, maternal rhinitis; Persistent/late - maternal education, smoking during pregnancy, maternal asthma, paternal asthma, maternal 
 Pike 16 
 
rhinitis; Persistent/late wheeze with atopy-child’s gender, maternal asthma, paternal asthma, paternal rhinitis, pets in the home during infancy; 
Persistent/late wheeze without atopy-maternal age, smoking during pregnancy, maternal asthma, paternal asthma, pets in the home during 
infancy.
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Atopy and eNO 
Maternal 25-hydroxyvitamin D status at 34 weeks’ gestation was not associated with skin 
sensitisation at 1, 3 or 6 years or with exhaled nitric oxide at age 6 years (Table 4). There was 
no evidence for a non-linear relationship between maternal 25-hydroxyvitamin D and either 
skin sensitisation or eNO (data not shown). 
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Table 4 Relationship between maternal late-pregnancy maternal 25-hydroxyvitamin D status and offspring atopy and airway inflammation 
  
Univariable Model 
   
Final model 
  
 
RR (95% CI) P-value n RR (95% CI) P-value n 
Atopy age 1 year 0.94 (0.88, 1.01) 0.08 773 0.96 (0.90, 1.03) 0.24 685 
Atopy age 3 years 0.99 (0.94, 1.05) 0.81 676 0.99 (0.94, 1.04) 0.58 661 
Atopy age 6 years 0.97 (0.93, 1.02) 0.26 635 0.99 (0.95, 1.04) 0.71 545 
 beta (95% CI) P-value n beta (95% CI) P-value n 
Exhaled nitric oxide -0.014 (-0.044,0.016) 0.36 451 -0.0204 (-0.050,0.009) 0.18 434 
 
Data presented as change in relative risk per 10 nmol/l change in maternal serum 25-hydroxyvitamin D status at 34 weeks’ pregnancy. 
Adjusted models: atopy age 1 year - child’s gender, parents’ social class, maternal atopy; atopy age 3 years - child’s gender, exposure to smoke 
in infancy, maternal eczema, atopy age 6 years - child’s age at testing, child’s gender, parents social class, maternal asthma, paternal rhinitis, 
maternal atopy; exhaled nitric oxide - child’s age at testing, maternal asthma, paternal rhinitis, maternal height.
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Lung function 
Maternal 25-hydroxyvitamin D at 34 weeks’ gestation was not associated with either absolute 
or standardised values of FEV1 or FVC at 6 years. Maternal 25-hydroxyvitamin D status was 
not associated with BHR (Table 5). There was no evidence for a non-linear relationship 
between maternal 25-hydroxyvitamin D and any measure of lung function (data not shown).
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Table 5 Relationship between maternal late-pregnancy maternal 25-hydroxyvitamin D status and offspring lung function at 6 years  
 Univariable Model Final Model 
 beta (95% CI) P-value n beta (95% CI) P-value n 
FEV1 absolute -0.0007 (-0.0054,0.0039) 0.76 739 -0.0001 (-0.0046,0.0043) 0.95 731 
FEV1 z-score 0.012 (-0.0078,0.033) 0.23 739 0.011 (-0.0091,0.031) 0.28 739 
FVC absolute -0.001 (-0.0068,0.0045) 0.69 739 -0.0001 (-0.0054,0.0052) 0.96 730 
FVC z-score 0.013 (-0.010,0.036) 0.27 739 0.012 (-0.011,0.035) 0.31 739 
BHR slope -0.084 (-0.194, -0.025) 0.13 216 -0.102 (-0.211, -0.008) 0.07 208 
 
Data presented as change in relative risk per 10 nmol/l change in maternal serum 25-hydroxyvitamin D status at 34 weeks’ pregnancy. 
Adjusted models: FEV1 absolute - child’s age at testing, child’s gender, parity, maternal BMI, maternal height; FEV1 z-score - child’s gender; 
FVC absolute - child’s age at testing, child’s gender, age at introduction of solid foods, maternal BMI, maternal height, FVC z-score - child’s 
gender; BHR - maternal age, smoking in pregnancy, paternal eczema, age at introduction of solid foods.
 Pike 21 
 
Alternative multivariable models 
Birthweight was not associated with any outcome and was therefore not considered a 
confounder. Gestation, however, was associated with all wheeze and skin sensitisation 
outcomes except current asthma and persistent/late wheeze with atopy; the absence of 
association between maternal 25-hydroxyvitamin D and these variables remained 
when gestation was included in the multivariable models. Birthweight was associated 
with absolute measures of FEV1 and FVC, but including birthweight in the 
multivariable models did not reveal any associations between maternal 25-
hydroxyvitamin D and these measures (Tables E1-3). When adjustments were made 
for season and year of blood sampling the absence of any association between 
maternal 25-hydroxyvitamin D and childhood wheeze, atopy or lung function 
variables was unchanged (Tables E4-6). 
 
Maternal vitamin D intake 
The median (IQR) average total daily maternal vitamin D intake was 4.2 mcg/day (3.0 
- 6.7 mcg/day). During early pregnancy 39% of women took supplements containing 
vitamin D, whilst during late pregnancy, 22% supplemented with vitamin D. For 
women taking supplements, median supplementary-intake (IQR) was 4.1 mcg/day 
(1.5-8.3 mcg/day) in early pregnancy and 5.8 mcg (2.5-12.2 mcg/day) vitamin D /day, 
in late pregnancy. Only 11.5% of women achieved an average intake of 10 mcg/day, 
currently recommended by the department of health.[23] Correlation coefficients for 
early, late and average intake with status at 34 weeks’ gestation were 0.25, 0.33 and 
0.33, respectively. Neither total nor food-derived maternal intake was associated with 
asthma, or any wheeze outcome (Tables E7 & E10). No significant associations were 
found between intake and skin sensitisation, (Tables E8 & E11) or any measure of 
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lung function (Tables E9 & E12). A statistically significant positive association was 
found between food-derived vitamin D and eNO (Table E5) but the lack of a similar 
association with total intake (Table E2) suggests that this is not a clinically robust 
association. There was no evidence for a significant association between total 
maternal vitamin D intake and any outcome when, for consistency with previous birth 
cohort analyses, the results were energy-adjusted and analysed as a categorical 
variable according to quartile of vitamin D intake (Tables E13-15).  
 
 
DISCUSSION 
This study found no evidence that higher maternal serum 25-hydroxyvitamin D in late 
pregnancy is associated with an increased risk of asthma or atopy. There were no 
significant associations between maternal 25-hydroxyvitamin D status at 34 weeks’ 
gestation and asthma, transient or persistent/late wheeze, skin sensitisation at 1, 3 or 6 
years or eNO, FEV1, FVC or BHR at age 6 years.  
 
It has been suggested that serum 25-hydroxyvitamin D levels in pregnancy should be 
above 80 nmol/l, 29% of the women in this study had serum 25-hydroxyvitamin D 
concentrations above this level. Both supplementation and 25-hydroxyvitamin D 
levels were higher in the current study than in our previous cohort where a positive 
association was found between maternal 25-hydroxyvitamin D status and childhood 
eczema and asthma.[5] Whilst a high prevalence of supplementation might reduce the 
ability of the present study to detect any effect of dietary insufficiency, failure to 
confirm a harmful effect of high 25-hydroxyvitamin D status cannot be attributed to 
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lower exposure; it is more likely that the earlier study was underpowered to assess 
specific clinical outcomes.  
 
Vitamin D supplementation during pregnancy is known to benefit calcium 
metabolism and bone health[24] and many believe may protect against cardiovascular, 
autoimmune, and malignant disease via ‘fetal imprinting’.[25] The National Institute 
for Health and Clinical Excellence[26] has suggested that pregnant women may wish 
to consider vitamin D supplementation. Recently a randomised controlled-trial has 
demonstrated that daily supplementation with 4000 IU vitamin D can increase 
maternal serum 25-hydroxyvitamin D concentration without adverse events.[27] 
However, few adequately powered studies have considered the effects of increased 
maternal 25-hydroxyvitamin D upon relevant clinical outcomes.[28] 
 
Relationship between maternal late-pregnancy serum 25-hydroxyvitamin D 
status and childhood asthma and wheeze  
This study found no evidence that higher late-pregnancy maternal serum 25-
hydroxyvitamin D is associated with increased asthma. Although an inverse 
relationship between energy-adjusted maternal vitamin D intake and asthma at age 5 
was found in a Finnish cohort,[6] this was significant only for food-derived not total 
intake. Associations with food derived intake only may be vulnerable to confounding 
by other nutrients present in vitamin D-rich food and socioeconomic factor or they 
may arise as a result of multiple comparisons. The majority of studies reporting 
inverse associations between early vitamin D exposure and adverse respiratory 
outcomes, reported associations with wheeze but not asthma. Many of these studies 
relied upon maternal intake data[6-9] and relatively short follow-up.[7-8]  
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Vitamin D intake studies are vulnerable to confounding by socio-economic and 
lifestyle factors and by the effects of other nutrients found in vitamin D-containing 
foods. Such confounding has been suggested to explain the absence of an association 
between 25-hydroxyvitamin D status and lung function in adults with chronic 
obstructive pulmonary disease, despite an association with vitamin D intake; absence 
of association between vitamin D receptor genotype and lung function strengthened 
this argument.[30] Studies with short follow-up are obliged to use childhood wheeze 
as an outcome in the absence of a reliable asthma diagnosis in young children. 
Follow-up to 5 years was conducted in a New Zealand cohort and an inverse 
association found between cord blood 25-hydroxyvitamin D and wheeze, but again no 
association was found with asthma.[29] An inverse association was also found 
between cord blood 25-hydroxyvitamin D status and respiratory infections in early 
infancy, leading these authors to conclude that beneficial effects of vitamin D upon 
innate immunity may indirectly reduce wheeze risk in early childhood. The present 
study did not address the issue of childhood infection. 
 
Relationship between maternal late-pregnancy serum 25-hydroxyvitamin D 
status and immune and respiratory development 
Whilst it remains possible that vitamin D exerts an affect upon immune predisposition 
to wheeze with infection, rather than altered atopic immunity, an alternative 
explanation for the lack of demonstrable association between early vitamin D 
exposure and asthma could be the existence of different asthma phenotypes. 
Subdividing the persistent/late wheeze phenotype by atopic status did not reveal any 
association with maternal vitamin D status, although it remains possible that the 
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phenotypes used in this study were excessively heterogeneous and that early vitamin 
D exposure may have differential effects upon late-onset compared with persistent 
wheeze, for example.  
 
Animal studies suggest vitamin D may promote a proallergic Th2 phenotype.[31] 
Similarly, epidemiological evidence suggests high early life exposure to vitamin D 
supplementation[32] or high maternal 25-hydroxyvitamin D serum levels might 
predispose to allergic disorders.[5] No previous prospective epidemiological study, 
however, has investigated the relationship between maternal 25-hydroxyvitamin D 
status and objective measures of atopy. In this respect, the null findings in this study 
are reassuring: higher serum 25-hydroxyvitamin D concentrations in late pregnancy 
do not appear to increase skin sensitisation at 1, 3 or 6 years or eosinophilic airways 
inflammation at 6 years. 
  
Early vitamin D exposure has been shown to alter the volume dependence of lung 
mechanics in an animal model, suggestive of altered tissue structure.[33] Altered 
development affecting lung structure and airway calibre would also be consistent with 
the results of maternal intake studies. However, this study confirms, in a larger cohort 
with more extensive characterisation of lung function including BHR, the findings of 
the KOALA study;[11] there was no evidence of a clinically significant alteration of 
lung function according to maternal late-pregnancy 25-hydroxyvitamin D status. 
 
As the repeatability of the serum 25-hydroxyvitamin D levels is relatively low, there 
is a significant chance that a single serum measurement will lead to misclassification 
of exposure. As this misclassification is random, this may bias studies, such as this, 
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based upon single serum samples toward the null or no effect. Furthermore, 
epidemiological studies are limited in their ability to discriminate causal from closely 
linked factors; this study cannot exclude the existence of a relationship between 
vitamin D exposure and wheeze or atopy which is hidden by an opposing relationship 
between incompletely controlled for seasonal and other factors upon these outcomes. 
Another feature of the study design which may have limited the likelihood of 
identifying an association between maternal 25-hydroxyvitamin D status and 
childhood wheeze outcomes is the use of frequent prospective questionnaires; this 
may have set too low a threshold to reflect significant pathology.  
 
Whilst the present study did not have complete follow-up and those followed up 
differed from those who were not in terms of several socioeconomic variables, this 
should not alter the main conclusions unless the nature of any relationship between 
maternal 25-hydroxyvitamin D status and wheeze or atopic outcomes differed 
according to socioeconomic status or if the relationship were non-linear. We have no 
evidence to support either assertion. The null results in this study may have arisen as a 
consequence of measuring 25-hydroxyvitamin D status in late pregnancy only, 
however, whilst much respiratory development, particularly that of the airways, 
occurs early in pregnancy,[34] significant maturation of the immune system is 
believed to occur in late pregnancy.[35] Furthermore, the null result was supported by 
analyses based upon intake data which covered both the first and second trimesters.  
 
In summary, neither higher late-pregnancy maternal 25-hydroxyvitamin D status nor 
high vitamin D intake during pregnancy was significantly associated with asthma or 
any wheeze phenotype. Moreover there was no evidence that early exposure to higher 
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concentrations of 25-hydroxyvitamin D had a deleterious effect upon either lung 
function or atopic sensitisation. Together, these findings suggest the risk posed by 
vitamin D supplementation in terms of asthma and atopic diseases may not be a 
concern.
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